CDIO

These evidence-based solutions help employers, brokers, and unions tackle cardiovascular disease, a leading driver of medical claims and lost productivity. Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, today announced that the company will exhibit at four upcoming national benefits conferences, connecting with employers, brokers, union trustees, and plan administrators on a shared challenge: cardiovascular disease (CVD). CVD remains a leading medical claims cost driver for most health plans and a major contributor to absenteeism, disability, and lost workforce productivity. Cardio Diagnostics' clinically validated blood tests,

AUSTIN, Texas, May 20, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Meesha Dogan, CEO and Co-Founder of Cardio Diagnostics Holdings Inc. (NASDAQ:CDIO), a precision cardiovascular medicine company leveraging epigenetics, genetics,

10-Q - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

AUSTIN, Texas, April 08, 2026 (GLOBE NEWSWIRE) -- via IBN -- Cardio Diagnostics Holdings Inc. (NASDAQ:CDIO), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, has engaged IBN, a multifaceted financial news and publishing company serving private and public entities, to assist with its corporate communications strategy. Cardio Diagnostics develops and commercializes blood-based clinical tests and data solutions designed to support the prevention, detection, and management of cardiovascular disease. Its approach integrates epigenetic and genetic biomarkers with artificial intel

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

10-K - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

8-K - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) ("Cardio Diagnostics" or the "Company"), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Wednesday, February 18, 2026, at 3 p.m. Central Time. The call will provide an overview of the Company's precision molecular approach to cardiovascular disease prevention and early detection, including updates on its commercially available tests, Epi+Gen CHD™ and PrecisionCHD™, recent breakthrough clinical data, reimbursement progress, and strategic growth initiatives. Web

Agreement expands Cardio Diagnostics' global footprint and supports improved detection and management of coronary heart disease in India. Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), a leader in epigenetics and AI-driven Precision Cardiovascular Medicine, Aimil Ltd., a company at the forefront of the instrumentation industry in India since 1932, introducing innovative, best-in-class technologies from around the world to their extensive healthcare network throughout India, and Dr. Lal PathLabs, one of India's most trusted service provider of diagnostic and related healthcare tests with 290+ clinical laboratories and 300+ MD pathologists in their internal network, today announced a stra

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

Southdale YMCA, part of YMCA of the North, becomes the second YMCA location nationally to partner with Cardio Diagnostics, expanding community access to AI-powered cardiovascular testing and education Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, today announced a new partnership with the Southdale YMCA to bring expanded heart health education and advanced cardiovascular testing to their members and the broader Edina community. The Southdale YMCA primarily serves the Edina, Richfield, Bloomington, and South Minneapolis areas, supporting more than 14,000 individuals, approximately 80% of whom are adults. This collaboration build

The final gapfill payment rate for both the Epi+Gen CHD™ and PrecisionCHD™ tests is higher at $854 compared to the preliminary gapfill payment rates of $350 for Epi+Gen CHD™ and $684.76 for PrecisionCHD™. Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, today announced that the Centers for Medicare and Medicaid Services (CMS) has issued a final gapfill payment rate of $854 for both the Epi+Gen CHD™ and PrecisionCHD™ tests. This finalized rate represents an increase from the preliminary gapfill payment rates of $350 for Epi+Gen CHD™ and $684.76 for PrecisionCHD™. Obtaining the final rate represents a positive development and will be e

10-Q - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

Ischemia with No Obstructive Coronary Arteries (INOCA) and Myocardial Infarction with No Obstructive Coronary Arteries (MINOCA) are two underdiagnosed, potentially fatal forms of heart disease that standard diagnostic testing routinely fails to detect Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-powered Precision Cardiovascular Medicine company, today announced that the Company will be presenting new data at the American Heart Association (AHA) Scientific Sessions demonstrating that the epigenetic biomarkers of the Company's PrecisionCHD test are able to detect Ischemia with No Obstructive Coronary Arteries (INOCA) and Myocardial Infarction with No Obstructive Coronary Arteries (

A customized program for YMCA of East Tennessee members will include educational series "Wisdom Wednesdays," and access to Cardio Diagnostics' AI-powered cardiovascular testing at discounted rates from home or during the Heart Health Fair Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, today announced that the Company is partnering with YMCA of East Tennessee to launch a customized program exclusively for its members. Through this program, YMCA members will learn how to take proactive steps to prevent and detect heart disease early while gaining access to Epi+Gen CHD™ and PrecisionCHD™ clinical tests from Cardio Diagnostics at a sp

Growing Adoption of AI-Driven Precision Cardiovascular Medicine Tests Spans Concierge, Functional Medicine, and Primary Care Practices Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven Precision Cardiovascular Medicine company, today announced the Company has partnered with 15 new provider organizations across the United States. This expansion demonstrates the continued adoption of the Company's innovative blood tests, Epi+Gen CHD™ and PrecisionCHD™, which are transforming the prevention, detection, and management of coronary heart disease across diverse clinical settings. The new provider organizations represent various medical specialties and care models, spanning four maj

8-K - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)